Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@jax.org
| NCT ID | NCT01986348 |
| Title | Phase 2 Study of Selinexor (KPT-330) in Patients With Recurrent Glioblastoma After Failure of Radiation and Temozolomide |
| Acronym | KING |
| Recruitment | Terminated |
| Gender | both |
| Phase | Phase II |
| Variant Requirements | No |
| Sponsors | Karyopharm Therapeutics, Inc |
| Indications | |
| Therapies | |
| Age Groups: | adult |
| Covered Countries | USA | NLD |
| Facility | Status | City | State | Zip | Country | Details |
|---|---|---|---|---|---|---|
| Massachusetts General Hospital | Boston | Massachusetts | 02114 | United States | Details | |
| Dana Farber Cancer Institute, Center for Neuro-Oncology | Boston | Massachusetts | 02215 | United States | Details | |
| Columbia University, Herbert Irving Comprehensive Cancer Center | New York | New York | 10032 | United States | Details | |
| The Phase I Unit, Dept. of Oncology, Rigshospitalet | Copenhagen | DK-2100 | Denmark | Details | ||
| University of Groningen Faculty of Medical Sciences, Medical Oncology | Groningen | 9713 GZ | Netherlands | Details | ||
| Erasmus MC-Daniel den Hoed Cancer Center- Neuro-Oncology Unit | Rotterdam | 3008AE | Netherlands | Details |